Drug-resistant tuberculosis control in China: progress and challenges

Infectious Diseases of Poverty
Qian LongHenry Lucas

Abstract

China has the second highest caseload of multidrug-resistant tuberculosis (MDR-TB) in the world. In 2009, the Chinese government agreed to draw up a plan for MDR-TB prevention and control in the context of a comprehensive health system reform launched in the same year. China is facing high prevalence rates of drug-resistant TB and MDR-TB. MDR-TB disproportionally affects the poor rural population and the highest rates are in less developed regions largely due to interrupted and/or inappropriate TB treatment. Most households with an affected member suffer a heavy financial burden because of a combination of treatment and other related costs. The influential Global Fund programme for MDR-TB control in China provides technical and financial support for MDR-TB diagnosis and treatment. However, this programme has a fixed timeline and cannot provide a long term solution. In 2009, the Bill and Melinda Gates Foundation, in cooperation with the National Health and Family Planning Commission of China, started to develop innovative approaches to TB/MDR-TB management and case-based payment mechanisms for treatment, alongside increased health insurance benefits for patients, in order to contain medical costs and reduce financial barriers to...Continue Reading

References

Mar 21, 2006·Lancet·Mario C Raviglione, Mukund W Uplekar
Aug 31, 2006·Health Policy and Planning·B XuL Bogg
Apr 22, 2009·Lancet·Margaret Harris Cheng
Nov 18, 2009·Tropical Medicine & International Health : TM & IH·Qin LiuPaul Garner
May 22, 2010·Lancet·Knut LönnrothMario C Raviglione
Jun 24, 2010·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Xiao-Yan YangSi-Miao Wu
Sep 10, 2010·The New England Journal of Medicine·Eva NathansonMario Raviglione
Nov 3, 2010·Journal of Health Economics·Christoph M Schmidt, Harald Tauchmann
Nov 5, 2010·The New England Journal of Medicine·Salmaan Keshavjee, Paul E Farmer
Oct 18, 2011·Emerging Infectious Diseases·Guang Xue HeSusan van den Hof
Mar 6, 2012·Lancet·Winnie Chi-Man YipAlan Maynard
Jun 8, 2012·The New England Journal of Medicine·Yanlin ZhaoYu Wang
Nov 10, 2012·PLoS Medicine·David HipgraveHana Brixi
Mar 28, 2013·The Lancet Infectious Diseases·Ibrahim AbubakarAlimuddin Zumla
Jul 24, 2013·The International Journal of Health Planning and Management·Shenglan TangHenk Bekedam
Dec 19, 2013·TheScientificWorldJournal

❮ Previous
Next ❯

Citations

Jan 30, 2016·Infectious Diseases of Poverty·Shenglan TangDaniel P Chin
Oct 21, 2017·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Hai HuangHui Gan
Jul 13, 2019·Tropical Medicine & International Health : TM & IH·Wenhui MaoShenglan Tang
Feb 27, 2020·International Journal of Environmental Research and Public Health·Qian LongShenglan Tang
Nov 12, 2020·Risk Management and Healthcare Policy·Peize ZhangGuofang Deng

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.